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Background: This study estimated the healthcare resource utilisation and costs of chronic
obstructive pulmonary disease (COPD) patients, staged by severity, in the Italian
pneumology departments (PDs).
Methods: The project was a multi-centre observational study conducted in 11 Italian PDs
throughout the country.
A total of 268 patients were recruited and followed prospectively for 1 year. For the
purpose of analysis, patients were divided into four groups according to the severity at
onset:
mild COPD (stage I)—postbronchodilator FEV1/FVCo70% and FEV1X 80% of predicted;
moderate COPD (stage II)—postbronchodilator FEV1/FVC o70% and 50% pFEV1o 80%
of predicted;
severe COPD (stage III)—postbronchodilator FEV1/FVC o70% and 30% pFEV1 o50% of
predicted;
very severe COPD (stage IV)—postbronchodilator FEV1/FVC o70% and FEV1 o30% of
predicted, or clinical signs of either respiratory or cardiac failure.Elsevier Ltd. All rights reserved.
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Healthcare costs of COPD in Italy 2313Results: Subgroups differed significantly in the main demographic and clinical variables.
Broadly, higher severity was associated with older age, longer disease duration, and more
frequent exacerbations. Patients with severe COPD used more resources for almost all
services than those with mild and moderate forms.
The annual average cost per patient was h3040.2 (h1046.7 for mild, h2319.0 for moderate,
h3572.1 for severe and h5033.3 for very severe forms).
Conclusions: This study offers some information on the healthcare costs of COPD induced
by PDs in Italy, potentially useful for decision-making in the health care services. Resources
and costs rose significantly with disease severity.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of chronic morbidity and mortality worldwide; its
global prevalence is estimated as 9.3% in men and 7.3% in
women.1 Risk factors include host factors and environmental
exposures, which interact. The main risk factor is cigarette
smoking, but heavy exposure to occupational dust, low
socio-economic status, and inherited a-1 antitrypsin are
recognised as additional factors.1,2
COPD is usually diagnosed late as patients may be
insensitive to airflow obstruction and lack symptoms even
at low FEV1 (forced expiratory volume in 1 s). The smoking
population shows a decline in FEV1 of 50–60mL/year
compared approximately 20mL for non-smokers. The only
proven way to slow this course is to stop smoking.1
COPD management aims at preventing progression and
exacerbations, improving exercise tolerance and quality of
life, and reduction of mortality due to respiratory illness.
The disease and its exacerbations are treated mainly with
bronchodilators, corticosteroids, and, where needed, ad-
juvant therapy such as antibiotics, mucolytics, or vaccines;
long-term oxygen therapy (LTOT), mainly given to patients
with severe COPD, can lengthen their survival.1,2
The social and economic burden of COPD on patients and
society may be underestimated because of under-diagnos-
ing.1 Economic evaluations currently analyse costs according
to severity3–10 or separating the disease from its exacerba-
tions,11,12 some studies estimate the costs of the main
chronic clinical disorders related to COPD (i.e. emphysema
and chronic bronchitis) too.13–15
This study estimated the healthcare resource utilisation
and costs of COPD, staged by severity, in Italian pneumology
departments (PDs).Italian background
The Italian National Health Service (INHS) is a public service
funded by general taxation which provides universal cover-
age and comprehensive health care free at the point of
delivery.16
Primary care in Italy is mainly delivered by general
practitioners (GPs) (around 51,000 in the country). GPs act
as gatekeepers of higher levels of care and are paid on a per
capita basis; most of them still work single-handed without
auxiliary staff and links with other GPs.Private and public hospitals are reimbursed by the INHS
according to a national diagnosis related group (DRG)—like
system introduced in Italy in 1995. National tariffs should
cover the full cost of hospital admissions, but also serve as a
tool for income policy and budgeting health care providers.
Although tariffs were based on the results of a cost survey on
a limited sample of hospitals,17 they have been adopted
throughout the country. However, while private hospitals are
reimbursed by only tariffs, any public hospital deficits are
still covered by the INHS. Therefore, tariffs cannot be
considered the only source of funding for public hospitals.
The INHS makes extensive use of tariffs for outpatient care
too.
A National COPD register does not exist in Italy. According
to the Italian Association of Pneumologists, COPD is usually
treated under the INHS coverage, since it is a chronic
pathology and care is aimed at preventing progression and
exacerbations. COPD seems to be under diagnosed in
primary care by Italian GPs and consultation with pneumol-
ogists may be delayed, particularly in early disease stages.9
This leads to under-treatment and suboptimal management
of the disease. Even when COPD is diagnosed, treatment
patterns can vary a lot from guideline recommendations,
due to a lack of awareness among physicians.
Secondary care is mainly provided by PDs, while hospital
at home still plays a negligible role for treating COPD
patients. There was a total of 161 PDs in public hospitals
(78 North, 32 Centre and 51 South Italy) in 2003.18Methods and materials
The BIC project was a multi-centre observational study that
comprised two phases: a 6-month retrospective survey,
published apart,19 and a 12-month prospective survey in
2002–2003, whose results are shown here. We invited 14
Italian PDs throughout the country to participate voluntarily.
Since one centre did not respect the inclusion criteria for
the vast majority of patients and two others did not manage
to complete the 1-year follow up, 11 eventually took
part—five in the North, two in the Centre and four in the
South.
Centres were asked to enrol consecutively within two
months up to 30 patients who had attended their units and
matched the following criteria:(a) age over 40;
(b) smokers or ex-smokers;
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D. Koleva et al.2314(c) clinical diagnosis of COPD according to the G.O.L.D.
guidelines version existing at the time of the study
(progressive dyspnea, with cough, expectoration and/or
history of exposure to risk factors);(d) spirometry showing progressive airflow limitation, not
fully reversible—postbronchodilator FEV1 o80% of its
predicted value, and FEV1/FVC (forced vital capacity)
ratio o70%. Spirometry was required at enrolment,
unless one was available within the previous month.Table 1 INHS outpatient tariffs used as unit costs
(Euros).
Diagnostic tests
Simple spirometry 23.2
Complete spirometry 37.2
Blood gas analysis 13.7
Chest radiography 15.5
Electrocardiogram 11.6
Laboratory tests
Haemochrome 3.2
Routine sputum culture 27.2
Hepatic enzymes 3.5
BUN 2.5
Physical therapy (10 treatment sessions)
Respiratory exercises 11.4
Other respiratory procedures 8.2
Specialist consultationsy 20.7
BUN, Blood urea nitrogen; INHS, Italian National Health
Service.
Specialist outpatient consultations covered by the NHS
under its tariff (‘‘Prestazioni di assistenza specialistica
ambulatoriale erogabili nell’ambito del Servizio Sanitario
Nazionale e relative tariffe’’—D.M. 22 July 1996).
yNon-pneumologic consultations.Patients were not eligible if enrolled in clinical trials, with
bronchial asthma, neoplasms or severe organ failure. A total
of 294 patients were eventually recruited because seven PDs
did not manage to enrol 30. The analysis comprised 268
patients since PDs declared 26 dropouts (23 males and 3
females, mean age 72, mean FEV1 49%); three patients
withdrew their consent, 23 were lost during the study
(11 died).
For the purpose of analysis, we classified patients in four
groups according to the severity, measured by spirometry of
the new G.O.L.D. classification1:
Stage I: Mild COPD—postbronchodilator FEV1/FVC o70%
and FEV1 X80% of predicted.
Stage II: Moderate COPD—postbronchodilator FEV1/FVC
o70% and 50%pFEV1 o80% of predicted.
Stage III: Severe COPD—postbronchodilator FEV1/FVC o
70% and 30% pFEV1 o50% of predicted.
Stage IV: Very Severe COPD—postbronchodilator FEV1/
FVC o70% and FEV1 o30% of predicted, or clinical signs of
either respiratory or cardiac failure.
The study was conducted according to the INHS perspec-
tive, so only healthcare costs were included.
Resource consumption
Patients were followed up according to the routine clinical
practice of PDs. At baseline, pneumologists entered general
information on each patient’s demographic and clinical
characteristics. At every contact pneumologists recorded
information on a predesigned questionnaire on the patients’
utilisation of health care services. Data were collected on a
quarterly basis and regularly sent to the coordinating centre
where two researchers checked their quality and consis-
tency. Information on resource use induced by referral
centres included: specialist consultations, emergency visits,
diagnostic and laboratory tests, LTOT, physical therapy,
hospital admissions and drugs. To quantify the real con-
sumption of each drug, the daily dose prescribed was
multiplied by the number of days of therapy.
Cost estimates
Days of stay, day-hospital (DH) days and outpatient
consultations were priced using estimates from a microcost-
ing study conducted in six PDs throughout the country which
could provide cost accounting information for 2004.20 The
full-cost method was used.21 Direct costs and overheads
were considered, but not capital account funds. Direct costs
included medical and non-medical staff’s wages, supplies
and equipment used in the PDs. Overheads comprised
general services (e.g. administration, housekeeping, power,and heating), and a share of costs incurred indirectly to
provide the service involving the utilisation of other units by
the PDs. These costs were allocated using a step-down
procedure.22 This led to an estimate of h268.2 for the
average cost of a day of stay, h473.8 for a DH day and h85.4
for an outpatient consultation. The costs of a DH day and a
day of stay did not include in-patient tests, physiotherapy
and pharmaceutical expenditures, because these were
estimated separately in the BIC project.
All specialist consultations (other than with pneumolo-
gists), diagnostic tests and physiotherapies were priced
applying the INHS tariffs (Table 1). Dispensing prices per unit
were used for drugs prescribed in the community, and a 50%
discount on dispensing prices was applied for drugs
purchased by hospitals (i.e. the minimum discount fixed by
law for public procurement of drugs).
To estimate LTOTcosts, liquid oxygen (the type used most
in Italy)23 was priced differently according to the purchasing
process. When dispensed through community pharmacies,
the INHS tariff for galenics was applied (h255 per month),
while for public procurement we used an average cost (h203
per month) based on a sample of 15 local health authorities
throughout Italy.24Data analysis
Continuous variables are presented as means with con-
fidence intervals (CIs), categorical ones as absolute and
relative frequencies. Costs were calculated by multiplying
the resources consumed by the specific unit costs identified
as above.
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Healthcare costs of COPD in Italy 2315To test statistical differences between groups, categorical
variables were analysed using the Pearson w2 test, contin-
uous ones by analysis of variance (ANOVA).
Since the distributions of resources and costs were
severely skewed, the 95% CIs were calculated with a non-
parametric bootstrap statistical method.25Results
Table 2 shows the main baseline characteristics. Of the
268 patients enrolled only 26 (9.7%) were newly diagnosed
(i.e. for the first time at study recruitment or within a
year before). Males predominated (84.9%) and the mean
age was 69.4 years. The disease duration was 11.5 years
on average, FEV1 was 55.7% of predicted and the mean
number of exacerbations was 0.8. Fifty-six patients had
mild COPD, 90 moderate, 52 severe and 70 very severe
forms. As expected, subgroups differed significantly in the
main demographic and clinical variables. Broadly, greaterTable 2 Patients’ main characteristics at baseline.
TOTAL (268) Mild (stage I) (56) Moderate (
No. (%) No. (%) No.
Sexy
Male 225 (84.9) 39 (69.6) 80
Female 40 (15.1) 17 (30.4) 9
Mean age 69.4 64.0 70.2
Range (SD) 36–88 (9.7) 36–86 (12.2) 49–86
Occupationy
Employed 36 (13.6) 13 (23.2) 15
Unemployed 12 (4.5) 4 (7.1) 5
Retired 170 (64.2) 34 (60.7) 58
Disability pension 47 (17.7) 5 (8.8) 11
Years of education y,z
0–5 161 (61.2) 28 (50.0) 55
6–8 57 (21.7) 11 (19.6) 20
9–13 33 (12.5) 11 (19.6) 9
413 12 (4.6) 6 (10.7) 4
Smoking habitsy
Smokers 60 (22.5) 21 (37.5) 21
Ex-smokers 207 (77.5) 35 (62.5) 68
Mean pack-year 34.1 25.6 37.1
Range (SD) 1–150 (21.7) 1–60 (18.1) 2–95
Mean duration of COPD (years) 11.5 7.3 11.5
Range (SD) 0–52 (10.0) 0–30 (7.9) 0–52
Mean FEV1/FVC (%) 55.1 65.7 58.1
Range (SD) 19–69 (11.5) 53–69 (3.7) 40–69
Mean FEV, (%) 55.7 88.5 62.4
Range (SD) 17–108 (22.4) 80–108 (7.8) 50–79
Mean exacerbationsz 0.8 0.5 0.8
Range (SD) 0–5 (1.0) 0–3 (0.8) 0–5
COPD, Chronic obstructive pulmonary disease; FEV1, Forced expir
deviation.
Pearson w2 for categorical variables and analysis of variance (ANO
yThe number of patients does not add up the total because of som
zThe classes have been set according to the duration of the It
university).
y27 patients had FEV1 X30, but with clinical signs of either respir
zExacerbations were defined according to the G.O.L.D. guidelinesseverity was associated with older age, higher male
proportion, longer disease duration and more frequent
exacerbations.
Table 3 shows the annual resource consumption per
patient. Patients received 6.6 diagnostic procedures and
laboratory tests per year; the most frequent procedures
were blood gas analysis and spirometry (both 2.4 per year).
Patients consulted specialists 4.2 times per year on average
(almost exclusively pneumologists), were assigned 3.4
physical therapy sessions, and were admitted to hospital
less than once per year on average. Patients with severe and
very severe COPD used more resources for almost all
services than those with mild and moderate forms. DH days
were the only item that did not differ significantly by
subgroup.
Table 4 shows the number of patients treated with drugs
by pharmaceutical group and LTOT. Eleven patients (4.1%)
did not receive drugs at all. Beta2-agonists and their asso-
ciations were the commonest drugs prescribed (86.6%),
followed by corticosteroids (59.7%) and anticholinergicsstage II) (90) Severe (stage III) (52) Very severe (stage IV) (70) p
(%) No. (%) No. (%)
(89.9) 47 (92.2) 59 (85.5) 0.003
(10.1) 4 (7.8) 10 (14.5)
70.9 71.6 o0.001
(7.6) 52–86 (8.4) 50–88 (9.2)
0.001
(16.8) 5 (9.8) 3 (4.3)
(5.6) 1 (2.0) 2 (2.9)
(65.2) 38 (74.5) 40 (58.0)
(12.4) 7 (13.7) 24 (34.8)
0.138
(62.5) 30 (60.0) 48 (69.6)
(22.7) 13 (26.0) 13 (18.8)
(10.2) 5 (10.0) 8 (11.6)
(4.6) 2 (4.0) 0 (0.0)
0.003
(23.6) 11 (21.1) 7 (10.0)
(76.4) 41 (78.9) 63 (90.0)
39.4 33.3 0.003
(20.1) 1–150 (26.9) 5–90 (20.2)
12.2 14.3 0.001
(10.2) 0–42 (9.9) 0–51 (10.3)
50.2 46.6 o0.001
(7.3) 24–68 (11.3) 19–68 (12.0)
41.3 32.1y o0.001
(8.0) 31–49 (5.3) 17–49 (8.5)
1.1 1.0 0.001
(1.0) 0–4 (1.1) 0–5 (1.1)
atory volume in 1 s; FVC, Forced vital capacity; SD, standard
VA) for continuous ones.
e missing data.
alian school system (primary, secondary and high school, and
atory or cardiac failure.
.
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Table 3 Resource consumption per patient per year.
TOTAL (268) Mild
(stage I) (56)
Moderate
(stage II) (90)
Severe
(stage III) (52)
Very severe
(stage IV) (70)
p
Mean Mean Mean Mean Mean
(CI)y (CI)y (CI)y (CI)y (CI)y
Diagnostic
tests
6.6 (5.9–7.4) 3.3 (2.5–4.5) 6.3 (5.4–7.4) 8.0 (6.5–10.2) 8.6 (7.1–10.6) o0.001
Blood gas
analysis
2.4 (2.1–2.8) 0.7 (0.4–1.1) 2.1 (1.8–2.5) 2.9 (2.3–3.8) 3.8 (3.1–5.0)
Spirometry 2.4 (2.0–2.6) 1.7 (1.2–2.3) 2.5 (2.0–3.1) 3.0 (2.3–4.0) 2.2 (1.7–2.9)
Chest
radiography
0.9 (0.8–1.1) 0.4 (0.3–0.7) 0.8 (0.7–1.1) 1.1 (0.8–1.5) 1.3 (1.0–1.7)
Others 0.9 (0.8–1.1) 0.5 (0.4–0.8) 0.9 (0.7–1.1) 1.0 (0.7–1.5) 1.3 (1.0–1.6)
Laboratory
tests
6.6 (5.6–7.8) 1.9 (0.9–3.6) 5.4 (4.1–7.2) 9.1 (6.3–13.4) 10.1 (7.8–12.6) o0.001
Hepatic
enzymes
2.4 (2.0–2.8) 0.7 (0.3–1.5) 1.9 (1.4–2.6) 3.3 (2.1–5.2) 3.6 (2.8–4.5)
BUN 1.7 (1.4–2.0) 0.5 (0.2–1.0) 1.4 (1.1–1.9) 2.2 (1.5–3.2) 2.7 (2.1–3.4)
Haemochrome 1.1 (1.0–1.4) 0.3 (0.2–0.6) 1.0 (0.7–1.2) 1.5 (1.1–2.2) 1.8 (1.4–2.3)
Others 1.4 (1.1–1.7) 0.4 (0.2–0.8) 1.1 (0.8–1.7) 2.1 (1.4–3.3) 2.0 (1.4–3.1)
Specialist
consultations
4.2 (4.0–4.4) 3.2 (2.8–3.5) 4.3 (4.0–4.8) 4.6 (4.1–5.2) 4.5 (4.1–4.9) 0.001
Pneumologic 4.1 (3.8–4.3) 3.2 (2.8–3.5) 4.3 (4.0–4.7) 4.3 (3.8–4.9) 4.2 (3.9–4.6)
Non-
pneumologic
0.1 (0.0–0.2) 0.0– 0.04 (0.0–0.1) 0.3 (0.1–0.5) 0.3 (0.1–0.5)
Physical
therapies
3.4 (2.3–4.6) 0.5 (0.2–2.3) 2.8 (1.6–4.6) 3.5 (1.7–6.0) 6.3 (3.6–10.5) 0.006
Hospital
admissions
0.4 (0.3–0.5) 0.1 (0.0–0.2) 0.3 (0.2–0.5) 0.4 (0.3–0.8) 0.8 (0.6–1.1) o0.001
Day-hospital
days
0.1 (0.0–0.2) 0.04 (0.0–0.1) 0.2 (0.1–0.3) 0.2 (0.1–0.4) 0.1 (0.0–0.2) 0.145
BUN, Blood urea nitrogen.
Analysis of variance (ANOVA).
yBootstrapped bias-corrected and accelerated confidence interval (95%).
D. Koleva et al.2316(44.0%). Overall, pharmaceutical prescriptions increased
significantly with severity. Beta2-agonists and their combi-
nations were prescribed more for moderate and severe
forms, while anticholinergics mainly for the severe and very
severe COPD. LTOT was prescribed mainly for very severe
cases.
The annual average cost per patient was h3040.2
(Table 5). Hospital admissions and drugs were the largest
cost components, accounting together for about two-thirds
of the total. Other relevant items were specialist consulta-
tions and LTOT in mild and very severe groups (respectively,
25.5% and 27.7% of total cost) (Figure 1). Beta2-agonists and
their combinations were responsible for more than half of
drug costs. The mean total cost rose significantly with
severity (h1046.7 for mild, h2319.0 for moderate, h3752.1
for severe and h5033.3 for very severe). Significant
differences between subgroups were recorded for all the
cost items except DH days.Discussion
This study is one of the first attempts to assess prospectively
resource utilisation and costs of COPD in an Italian sample
of PDs.
Major limits must be kept in mind when assessing these
findings. First of all, we investigated costs in hospital
departments only, but COPD patients are also treated by GPs
in primary care. This might have led to recruiting a sample
of patients with greater severity than the average COPD
population. Although there are no epidemiological data on
COPD prevalence by severity in Italy to confirm it, our
severity rates were higher than in another Italian nationwide
study9 that included the primary care setting (26% vs 12%
severe and 21% vs 31% mild forms).
Secondly, the generalisability of our results to the whole
country may be limited by the non-random selection of PDs.
However, the number of participating PDs was fairly high for
ARTICLE IN PRESS
Table 4 Number of patients treated with drugs.
TOTAL
(268)
Mild
(stage I) (56)
Moderate
(stage II) (90)
Severe
(stage III) (52)
Very severe
(stage IV) (70)
p
No. (%) No. (%) No. (%) No. (%) No. (%)
Beta2-agonists and
combinations
232 (86.6) 44 (78.6) 82 (91.1) 49 (94.2) 57 (81.4) 0.031
Corticosteroids 160 (59.7) 18 (32.1) 57 (63.3) 35 (67.3) 50 (71.4) o0.001
Anticholinergics 118 (44.0) 12 (21.4) 39 (43.3) 33 (63.5) 34 (48.6) o0.001
Methylxanthines 99 (36.9) 11 (19.6) 35 (38.9) 20 (38.5) 33 (47.1) 0.015
Other drugsy 153 (57.1) 27 (48.2) 52 (57.8) 32 (61.5) 42 (60.0) 0.479
LTOT 68 (25.4) 1 (1.8) 12 (13.3) 11 (21.2) 44 (62.9) o0.001
No drugs 11 (4.1) 6 (10.7) 2 (2.2) 1 (1.9) 2 (2.9) 0.047
LTOT, long-term oxygen therapy.
Pearson w2 test.
yThe main groups were antibiotics, mucolytics/expectorans, vaccines, cardiovascular drugs, and anti-smoking drugs.
Healthcare costs of COPD in Italy 2317this sort of study and they were spread throughout Italy like
the 161 PDs based on public hospitals (of our centres North
45.4%, Centre 18.2%, South 36.4% vs 48.4%, 19.9%, 31.7% for
public hospital PDs). Therefore, their distribution should
guarantee results fairly representative of Italian referral
centres.
Another limitation is that we estimated the unit costs
of health care resources only in six PDs, then used
these estimates to calculate direct medical costs in all
participating centres. Ideally, the unit cost of health
care facilities should have been established by a detailed
micro-costing study in all participating PDs. However, a
hard costing exercise of this sort would have required
cost accounting information that not all centres had
available. Although these figures do not precisely reflect
the real costs in all hospitals, using the DRG tariffs only
instead of the real costs could have resulted in a more
biased cost estimate.
The main strength of the study is that information on
resource consumption and costs were prospectively re-
corded, with the same questionnaire, for 268 patients
during 1 year.
Our patients’ main epidemiologic characteristics were
substantially consistent with similar studies conducted
abroad,4,6–8 once severity staging differences had been
taken into account. The mean age (69 years) was similar to
those of Detournay et al. (67), Miravitlles et al. (66) and
Jansson et al. (64), our age by severity to Hilleman et al.
(mild 64, moderate 70 and severe 72 vs 63, 69 and 71). Sex
distribution was more similar to the French and Spanish
studies (85% males vs 82% and 78%, respectively), and
differed considerably from the Swedish study (57% males
and 43% females). The proportion of current smokers (23%),
number of pack-year (34) and disease duration (11 years)
were very similar to the results of the Spanish survey (21%,
33 and 12).
Resource consumption significantly increased with sever-
ity in our study, except for DH days. This might reflect the
very limited number of DH days recorded (34 in total)—more
than half the participating centres did not use DH
treatment.Costs of hospital admissions were by far the largest
component in our sample and were much higher for very
severe cases than in the three other groups, reflecting the
larger proportion of patients admitted (47% vs 27% severe,
21% moderate and 11% mild forms). Drugs were the second
cost component broadly, although they were by far
exceeded by LTOT in very severe patients, a therapy which
is more indicated in stage IV.1
In general, our study found costs increased with severity,
although this might be underestimated by the extensive
staging criteria adopted and the high proportion of patients
without exacerbations (43%), which are among the key
drivers in the costs of COPD.12 An Italian study limited to
three northern regions,10 with a similar sample as regards
age and sex, found comparable costs for mild and moderate
COPD once account had been taken for differences in
classification by severity. Although we used the same
criteria for the most advanced stage, the severe form
was associated with lower costs in this study (h3912 vs
h5033), maybe because they also enrolled non-smokers
(6.6%) and did not include LTOT, which accounted for a
large proportion of total costs in very severe cases in our
series. The same authors recently conducted another study
nationwide9 where 400 patients who self-assessed their
disease severity were followed through telephone inter-
views. Although non-smokers were only 0.2%, LTOT was
included this time, and the proportion of hospitalisation
costs was much higher than here (75% vs 41%), they still
recorded a lower mean cost per patient (h1261.3 vs
h3040.2).
It is harder to compare our study with economic
evaluations from other countries, because of monetary
differences and domestic features such as clinical practice
patterns and the health care framework.26,27 As already
mentioned, the evaluations on COPD may also differ
substantially depending on the guidelines adopted for
staging.
Nevertheless, once methodological differences are taken
into account, our general findings are substantially similar to
one study conducted in USA and three from Europe. The
American study6 assessed the costs of 413 patients followed
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Table 5 Average costs per patient per year (Euros).
TOTAL
(268)
Mild
(stage I)(56)
Moderate
(stage II)(90)
Severe
(stage III)(52)
Very severe
(stage IV)(70)
p
Mean % Mean % Mean % Mean % Mean %
(CI) (CI) (CI) (CI) (CI)
Diagnostic tests 130.6
(116.7–148.9)
4.3 79.7
(60.3–105.7)
7.5 128.5
(108.6–152.1)
5.5 151.7
(115.4–192.8)
4.0 158.3
(123.4–195.9)
3.2 0.003
Laboratory tests 29.3 (24.7–35.4) 1.0 9.2 (4.6–16.6) 0.9 26.1 (19.7–34.4) 1.1 40.7 (27.0–59.3) 1.1 40.9 (29.8–54.3) 0.8 0.002
Specialist consultations 330.8
(313.4–349.8)
10.9 267.3
(234.8–298.5)
25.5 350.4
(321.2–382.1)
15.1 348.4
(302.4–391.5)
9.3 343.5
(304.9–381.2)
6.8 0.007
Physical therapies 3.8 (2.7–5.2) 0.1 0.6 (0.2–2.2) 0.1 3.1 (1.8–5.2) 0.2 4.0 (2.0–6.9) 0.1 7.1 (3.9–11.9) 0.1 0.006
Drugs 700.9
(640.5–771.2)
23.0 440.4
(347.7–539.9)
42.1 789.8
(692.9–891.5)
34.1 820.4
(678.7–1027.2)
21.9 706.3
(565.6–894.0)
14.0 o0.001
Beta2-agonists and
combinations
429.3
(384.8–481.9)
14.1 336.9
(251.2–426.9)
32.2 510.8
(439.0–603.6)
22.0 441.6
(354.1–580.1)
11.8 389.5
(307.9–496.4)
7.7
LTOT 545.4 17.9 36.2 3.5 268.6 11.6 432.3 11.5 1392.6 27.7 o0.001
(432.9–671.5) (0.0–181.2) (143.3–465.2) (224.8–716.7) (1108.9–1657.3)
Hospital admissions 1239.7
(921.4–1830.4)
40.8 196.4
(86.2–426.2)
18.8 673.5
(375.5–1114.5)
29.0 1865.8
(808.5–5027.5)
49.7 2337.2
(1658.0–3508.6)
46.5 0.002
Day-hospital days 59.7 (38.9–87.1) 2.0 16.9 (8.5–59.2) 1.6 79.0 (47.4–131.6) 3.4 88.8 (41.0–200.5) 2.4 47.4 (27.1–108.3) 0.9 0.155
TOTAL COST 3040.2
(2606.1–3687.8)
100.0 1046.7
(837.4–1364.2)
100.0 2319.0
(1876.6–2970.1)
100.0 3752.1
(2486.6–7080.2)
100.0 5033.3
(4136.0–6240.1)
100.0 o0.001
Median 1583.0 643.7 1468.7 1530.0 3293.7 o0.001y
LTOT long-term oxygen therapy.
Analysis of variance (ANOVA).
Bootstrapped bias-corrected and accelerated confidence interval (95%).
yKruskal–Wallis test.
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Figure 1 Distribution of healthcare costs by severity.
Healthcare costs of COPD in Italy 2319retrospectively for 5 years. There was a significant increase
in the median yearly cost according to severity, similar to
our analysis. Hospitalisations, drugs and LTOTwere again the
main cost drivers in moderate and severe forms.
A 1-year French4 ambispective study of 255 patients
estimated a mean per-patient cost very similar to ours
(h2863); hospitalisations were the leading cost component,
like in our study (36% vs 41%), followed by drugs (24% vs 23%)
and LTOT (17% vs 18%).
In a Spanish prospective study, 268 GPs recruited 766
patients with COPD throughout the country and followed
them for 1 year.8 The proportion of hospitalisation costs
(44% vs 41%) was similar to ours and there was a tendency
for costs to rise with severity.
A telephonic survey7 conducted on a cohort of 212
patients from the largest epidemiologic studies in Northern
Sweden reported a highly significant relationship between
severity of disease and costs as well as hospitalisations and
drugs as main cost drivers. However, cost differences
between severity groups were far higher than ours (410
times higher for severe patients than for mild ones). This
might be due to the high proportion of non-smokers included
in this study (18.5%) and the absence of hospital admissions
for mild cases.
In conclusion, this study offers some information on the
healthcare costs of COPD induced by PDs in the INHS,
potentially useful for decision-making in the health care
services. Health care resources and costs increased with
disease severity, hospitalisations and drugs being the main
cost drivers. Early diagnosis and slowing disease progression
might reduce hospital admissions and improve rational
allocation of costs within the INHS in the long run.Conflict of interest and ethics statements
Each author states that ‘‘no financial or other potential
conflicts of interest exist’’.
Authors state that the work has been approved by the
appropriate ethical committees related to the institutions in
which it was performed and that subjects gave informed
consent to the work.Acknowledgement
The study was supported by a financial contribution from
Boehringer Ingelheim Italia SpA.References
1. National Heart, Lung and Blood Institute (NHLBI)/World Health
Organization (WHO) workshop report. Global Initiative for
Chronic Obstructive Lung Disease. Global Strategy for the
Diagnosis, Management and Prevention of Chronic Pulmonary
Disease. Bethesda: National Heart, Lung and Blood Institute,
[Revised Edition 2006; NIH publication no. 2701:1–100].
2. Sutherland ER, Cherniack RM. Management of chronic obstruc-
tive pulmonary disease. N Engl J Med 2004;350:2689–97.
3. Masa JF, Sobradillo V, Villasante C, et al. Costs of chronic
obstructive pulmonary disease in Spain: estimation from a
population-based study. Arch Bronchopneumol 2004;40:72–9.
4. Detournay B, Pribil C, Fournier M, et al. The SCOPE Study:
health-care consumption related to patients with chronic
obstructive pulmonary disease in France. Value Health 2004;
7(2):168–74.
5. O’Brien JA, Ward AJ, Jones MKC, McMillan C, Lordan N.
Utilization of health care services by patients with chronic
obstructive pulmonary disease. Resp Med 2003;97(Suppl.A):
S53–8.
6. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoe-
conomic evaluation of COPD. Chest 2000;118:1278–85.
7. Jansson SA, Andersson F, Borg S, Ericsson A, Jo¨nsson E, Lundba¨ck
B. Costs of COPD in Sweden according to disease severity. Chest
2002;122:1994–2002.
8. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic
bronchitis and COPD: a 1-year follow-up study. Chest 2003;
123:784–91.
9. Dal Negro R, Rossi A, Cerveri I. The burden of COPD in Italy:
results from the confronting COPD survey. Resp Med 2003;
97(Suppl. C):S43–50.
10. Dal Negro R, Berto P, Tornella S, Quareni L, on behalf of GOLD
Study Group. Cost-of-illness of lung disease in the Tri Veneto
Region, Italy: the GOLD Study. Monaldi Arch Chest Dis 2002;
57:1–7.
11. Oostenbrink JB, Rutten-van Mo¨lken MP. Resource use and risk
factors in high-cost exacerbations of COPD. Resp Med 2004;
98(9):883–91.
ARTICLE IN PRESS
D. Koleva et al.232012. Andersson F, Borg S, Jansson SA, et al. The costs of exacerba-
tions in chronic obstructive pulmonary disease (COPD). Resp
Med 2002;96(9):700–8.
13. Wilson L, Devine EB, So K. Direct medical costs of chronic
obstructive pulmonary disease: chronic bronchitis and emphy-
sema. Resp Med 2000;94:204–13.
14. Miravitlles M, Murio C, Guerriero T, Gisbert R, for the DAFNE Study
Group. Pharmacoeconomic evaluation of acute exacerbations of
chronic bronchitis and COPD. Chest 2002;121(5):1449–55.
15. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD.
Chest 2000;117(2 Suppl.):5S–9S.
16. France G, Taroni F. The evolution of health-policy making in
Italy. J Health Polit Policy Law 2005;30(1–2):169–87.
17. Taroni F. DRG/ROD e nuovo sistema di finanziamento degli
ospedali. Rome: Il Pensiero Scientifico Editore; 1996.
18. Ministero della salute: /http://www.ministerosalute.itS.
19. Motterlini N, Koleva D, Garattini L e Gruppo di Studio Progetto
BIC. I costi della BPCO in Italia: l’analisi retrospettiva dello
studio BIC. Economia & Politica del Farmaco 2005;4:20–8.
20. Motterlini N, Garattini L. I costi di struttura dei reparti di
pneumologia in Italia. FarmacoEconomia News 2007;3:3–7.21. Garattini L, Giuliani G, Pagano E. A model for calculating costs
of hospital wards: an Italian experience. J Manage Med
1999;13:71–82.
22. Drummond MF, O’Brien BJ, Stoddart GL, Torrance GW. Methods
for the economic evaluation of health care programmes.
Oxford: Oxford University Press; 1997.
23. Garattini L, Cornago D, Tediosi F. A comparative analysis of
domiciliary oxygen therapy in five European countries. Health
policy 2001;58:133–49.
24. Garattini L, Cornago D. Ossigenoterapia a lungo termine:
modalita` di acquisto e distribuzione in Italia. Economia &
Politica del Farmaco 2004;2:29–36.
25. Carpenter J, Bithell J. Bootstrap confidence intervals: when,
which, what? A practical guide for medical statisticians. Stat
Med 2000;19:1141–64.
26. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in
economic evaluation studies in healthcare: a review and
studies. Health Technol Assess 2004;8(49):1–192.
27. Boulenger S, Nixon J, Drummond M, Ulmann P, Rice S, de
Pouvourville G. Can economic evaluations be made more
transferable? Eur J Health Econom 2005;6:334–46.
